Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy save search
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
Published: 2022-07-26 (Crawled : 13:20) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 0.25%
H: 200.0%
C: 200.0%
drug candidate research liver pre-clinical therapy cancer publication
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: -0.68%
H: 168.71%
C: 113.61%
partnership lupus natural cell therapeutics therapy
Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures
Published: 2021-12-08 (Crawled : 13:30) - globenewswire.com
EHVVF | $0.001 155.0% 34K
|
Professional, Scientific, and T...
|
| O: 6.67%
H: 125.0%
C: 71.25%
distribution merge therapy
Kiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA
Published: 2020-12-17 (Crawled : 18:00) - biospace.com/
KRBP | $2.5 -90.21% 830
|
Health Technology
|
| O: -0.33%
H: 95.17%
C: -6.11%
fda therapy submission t-cell car-t application
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
Published: 2023-07-27 (Crawled : 15:20) - biospace.com/
URGN | $13.78 -3.37% -3.48% 390K
|
Health Technology
|
| O: 3.44%
H: 94.21%
C: 91.95%
ugn-102 trials potential therapy
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
Published: 2023-12-07 (Crawled : 13:00) - globenewswire.com
SLDB | $8.7 -6.05% -6.44% 110K
|
Health Technology
|
| O: 4.97%
H: 79.39%
C: 60.45%
sgt-003 fda designation duchenne therapy
Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline
Published: 2022-07-07 (Crawled : 21:00) - biospace.com/
KRBP | $2.5 -90.21% 830
|
Health Technology
|
| O: 3394.76%
H: 70.79%
C: 23.15%
biopharma therapy milestone
ATI Physical Therapy Announces Reverse Stock Split
Published: 2023-06-14 (Crawled : 10:00) - prnewswire.com
ATIP 4 | $4.16 1.46% -3.85% 3K
|
Manufacturing
|
| O: -1.16%
H: 70.59%
C: 17.18%
therapy
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
Published: 2024-04-10 (Crawled : 16:00) - globenewswire.com
ORGS | $0.5001 -2.34% -2.4% 60K
|
Health Technology
|
| O: 7.22%
H: 69.23%
C: 0.73%
partnership cell global therapy
Therapeutic Solutions International Files to Initiate Phase III Clinical Trial for Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive COVID-19 Data with JadiCell Stem Cell Therapy
Published: 2023-04-20 (Crawled : 15:00) - biospace.com/
TSOI | $0.0007 0.0% 33M
|
Manufacturing
|
| O: 0.0%
H: 61.54%
C: 7.69%
covid-19 respiratory positive international cell solutions trial therapy
Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter
Published: 2021-05-24 (Crawled : 13:00) - biospace.com/
KRBP | $2.5 -90.21% 830
|
Health Technology
|
| O: 5.02%
H: 52.24%
C: 17.91%
fda therapy submission t-cell fda ide car-t
RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis
Published: 2021-06-14 (Crawled : 18:00) - biospace.com/
RAPT | $7.96 0.38% 0.38% 790K
|
Health Technology
|
| O: 56.92%
H: 44.1%
C: 37.34%
phase 1 positive therapy results dermatitis topline trial atopic dermatitis phase 1b phase 2b
Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy
Published: 2021-10-27 (Crawled : 12:00) - globenewswire.com
KTTA | $7.15 -1.19% 540
|
|
| O: 2.95%
H: 43.37%
C: 6.09%
treatment therapy ketamine
Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy– Pasithea Clinics
Published: 2021-10-27 (Crawled : 12:15) - biospace.com/
KTTA | $7.15 -1.19% 540
|
|
| O: 2.95%
H: 43.37%
C: 6.09%
treatment therapy ketamine depression
Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19
Published: 2021-08-25 (Crawled : 14:00) - biospace.com/
ADTX | $2.31 -4.15% -4.33% 15K
|
Health Technology
|
| O: 40.4%
H: 42.09%
C: 9.35%
covid biopharma acquisition therapy antiviral
Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes
Published: 2022-11-03 (Crawled : 12:20) - biospace.com/
CELZ | $4.82 0.21% 0.21% 22K
|
|
| O: 19.85%
H: 41.67%
C: 4.17%
treatment fda clearance drug application technology diabetes therapy
New Publications Highlight Clinical Benefits of Avinger PAD Therapies
Published: 2021-04-21 (Crawled : 13:00) - biospace.com/
AVGR | $4.02 2.55% 2.49% 5.6K
|
Health Technology
|
| O: 1.03%
H: 40.82%
C: 24.49%
therapy publication
Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2022-12-29 (Crawled : 14:00) - prnewswire.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 102.05%
H: 40.61%
C: 20.58%
ht-001 treatment fda application therapeutics therapy cancer growth
Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation
Published: 2021-03-19 (Crawled : 13:30) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 20.3%
H: 39.84%
C: 22.81%
therapy cancer ovarian cancer
Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Published: 2023-01-13 (Crawled : 13:20) - globenewswire.com
JSPR | $21.61 -6.89% -7.4% 65K
|
|
| O: 23.64%
H: 39.71%
C: -12.75%
cibmtr therapeutics positive therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.